14 Best Pharma Dividend Stocks to Buy in 2025

Page 9 of 12

4. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 93

Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks in the pharma sector. The company has a strong lineup of products in development and brings in solid revenue and earnings. It remains focused on innovation, with recent regulatory approvals including Winrevair, a treatment for pulmonary arterial hypertension, and Enflonsia, a vaccine targeting respiratory syncytial virus (RSV).

Merck & Co., Inc. (NYSE:MRK) reported solid earnings in the first quarter of 2025. The company’s revenue came in at $15.5 billion, down nearly 2% from the same period last year, but beat analysts’ estimates by over $198 million. Sales of KEYTRUDA rose by 4% to reach $7.2 billion, or 6% growth when adjusted for foreign exchange effects. WINREVAIR brought in $280 million in revenue. Meanwhile, Merck’s Animal Health segment saw a 5% increase in sales to $1.6 billion, and a 10% rise when excluding the impact of currency fluctuations.

In addition to these quarterly earnings, Merck & Co., Inc. (NYSE:MRK) has shown its resilience as a dividend stock. The company has been rewarding shareholders with growing dividends for the past 14 years. Currently, it offers a quarterly dividend of $0.81 per share and has a dividend yield of 4.05%, as of July 17.

Page 9 of 12